Roche Pharma India has introduced a groundbreaking medication, Ocrevus, aimed at managing multiple sclerosis (MS) with the potential to delay its progression. MS, a leading cause of non-traumatic disability in young adults, primarily affects individuals aged between 20 and 40 years.

Ocrevus stands out as the only monoclonal antibody drug approved for treating both Relapsing-Remitting MS (RRMS) and Primary Progressive MS (PPMS). With over a decade of clinical and real-world data, its efficacy is remarkable.

The medication's biannual dosing schedule has contributed to its high persistence and superior adherence rates among patients. 

Approximately 80% of patients adhered to Ocrevus's twice-yearly dosing after their second year of treatment, surpassing other Disease Modifying Therapies (DMTs).

Ocrevus stands as the only MS treatment consistently proven to significantly slow disability progression across the MS spectrum. 

With over 300,000 patients treated globally, it represents a milestone in MS therapy.

V Simpson Emmanuel, CEO and Managing Director of Roche Pharma India, emphasized Ocrevus's formidable efficacy and long-term safety record. He highlighted its potential to address the growing burden of neurological disorders in India.

Renowned neurologist Padma Shri Dr. (Prof.) MV Padma Srivastava lauded Ocrevus as a breakthrough solution, particularly for individuals with persistent disease activity despite available treatments. Early initiation of treatment was recommended for optimal outcomes.

Sandeep Chitnis, National Honorary Secretary of the Multiple Sclerosis Society of India (MSSI), stressed the importance of early treatment initiation to minimize disease impact and extend patients' independence.

Dr. Viraj Suvarna, Chief Medical Officer at Roche Pharma India, emphasized Ocrevus's transformative potential in MS treatment. He highlighted its significant role in slowing disability progression and advocated for its adoption as the standard of care across all forms of MS.

Ocrevus, Roche's leading product globally, is approved for both relapsing and primary progressive MS in over 100 countries, including India. 

Its launch marks a significant advancement in MS therapy, promising improved outcomes and enhanced quality of life for patients nationwide.